These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37217392)

  • 1. Integrative approach for managing tardive dyskinesia: A case report.
    Kulamarva K; Karanth V; Chikkanna U; Bhargav H; Holla B; Ramakrishna KK; Jasti N; Varambally S
    Explore (NY); 2023; 19(6):865-867. PubMed ID: 37217392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Strategies for Tardive Dyskinesia.
    Kremens DE
    J Clin Psychiatry; 2019 Dec; 81(1):. PubMed ID: 31880872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tardive Dyskinesia: Treatment Update.
    Arya D; Khan T; Margolius AJ; Fernandez HH
    Curr Neurol Neurosci Rep; 2019 Aug; 19(9):69. PubMed ID: 31420757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valbenazine for the treatment of tardive dyskinesia.
    Seeberger LC; Hauser RA
    Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.
    McIntyre RS; Calabrese JR; Nierenberg AA; Farahmand K; Yonan C; Siegert S; Burke J
    J Affect Disord; 2019 Mar; 246():217-223. PubMed ID: 30583148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crushing deutetrabenazine for treatment of tardive dyskinesia in a patient with severe orofacial symptoms: A case report.
    Wietholter JP; Sizemore J; Piechowski K
    Am J Health Syst Pharm; 2020 Sep; 77(18):1477-1481. PubMed ID: 32761113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management.
    Salem H; Pigott T; Zhang XY; Zeni CP; Teixeira AL
    Expert Rev Neurother; 2017 Sep; 17(9):883-894. PubMed ID: 28750568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antipsychotic-induced tardive syndromes].
    Fleischhacker WW; Hofer A; Jagsch C; Pirker W; Psota G; Rittmannsberger H; Seppi K
    Neuropsychiatr; 2016 Sep; 30(3):123-130. PubMed ID: 27580887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A descriptive analysis of spontaneous reports of antipsychotic-induced tardive dyskinesia and other extrapyramidal symptoms in the Japanese Adverse Drug Event Report database.
    Saga Y; Chiang CL; Wakamatsu A
    Neuropsychopharmacol Rep; 2024 Mar; 44(1):221-226. PubMed ID: 37884014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients.
    Witter DP; Holbert RC; Suryadevara U
    Expert Opin Pharmacother; 2017 Jul; 18(10):965-972. PubMed ID: 28443349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
    Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of dose-dependent lithium-induced tardive dyskinesia.
    Akkus M
    J Affect Disord; 2022 Feb; 299():205-206. PubMed ID: 34871639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review on the use of clozapine in treatment of tardive dyskinesia and tardive dystonia in patients with psychiatric disorders.
    Wong J; Pang T; Cheuk NKW; Liao Y; Bastiampillai T; Chan SKW
    Psychopharmacology (Berl); 2022 Nov; 239(11):3393-3420. PubMed ID: 36180741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of tardive dyskinesia: an updated review of the literature.
    Lanning RK; Zai CC; Müller DJ
    Pharmacogenomics; 2016 Aug; 17(12):1339-51. PubMed ID: 27469238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data.
    Preskorn SH; Macaluso M
    J Psychiatr Pract; 2016 Mar; 22(2):117-23. PubMed ID: 27138080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tardive Dyskinesia: New Treatments Available.
    Limandri BJ
    J Psychosoc Nurs Ment Health Serv; 2019 May; 57(5):11-14. PubMed ID: 31042295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.